Eli Lilly and Co (NYSE:LLY) – Stock analysts at SunTrust Banks upped their FY2018 earnings per share (EPS) estimates for Eli Lilly and in a report released on Thursday. SunTrust Banks analyst J. Boris now expects that the company will post earnings of $4.91 per share for the year, up from their prior forecast of $4.82. SunTrust Banks also issued estimates for Eli Lilly and’s FY2019 earnings at $5.41 EPS, FY2020 earnings at $6.16 EPS and FY2022 earnings at $7.39 EPS.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. Eli Lilly and had a positive return on equity of 31.44% and a negative net margin of 0.89%. The company had revenue of $6.16 billion during the quarter, compared to the consensus estimate of $5.93 billion. During the same quarter in the prior year, the firm earned $0.95 EPS. The company’s quarterly revenue was up 7.0% compared to the same quarter last year.

LLY has been the subject of a number of other research reports. BMO Capital Markets set a $73.00 target price on Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, October 24th. Berenberg Bank restated a “buy” rating and issued a $98.00 target price on shares of Eli Lilly and in a report on Thursday, October 26th. Zacks Investment Research lowered Eli Lilly and from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Credit Suisse Group restated a “hold” rating on shares of Eli Lilly and in a report on Wednesday, December 13th. Finally, Leerink Swann increased their target price on Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a report on Monday, October 23rd. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $92.02.

Shares of Eli Lilly and (NYSE:LLY) traded up $0.79 during trading hours on Monday, hitting $76.44. The stock had a trading volume of 1,937,195 shares, compared to its average volume of 5,310,823. Eli Lilly and has a one year low of $73.69 and a one year high of $89.09. The firm has a market cap of $83,870.00, a P/E ratio of -382.20, a PEG ratio of 1.42 and a beta of 0.23. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Quantitative Investment Management LLC increased its position in Eli Lilly and by 1.0% during the fourth quarter. Quantitative Investment Management LLC now owns 124,800 shares of the company’s stock worth $10,540,000 after buying an additional 1,200 shares during the last quarter. Nomura Asset Management Co. Ltd. increased its position in Eli Lilly and by 24.4% during the fourth quarter. Nomura Asset Management Co. Ltd. now owns 760,060 shares of the company’s stock worth $64,195,000 after buying an additional 148,955 shares during the last quarter. BlueCrest Capital Management Ltd acquired a new position in Eli Lilly and during the fourth quarter worth $20,533,000. Thrivent Financial For Lutherans increased its position in Eli Lilly and by 51.4% during the fourth quarter. Thrivent Financial For Lutherans now owns 139,846 shares of the company’s stock worth $11,812,000 after buying an additional 47,461 shares during the last quarter. Finally, Strategic Capital Advisers Inc. acquired a new position in Eli Lilly and during the fourth quarter worth $2,021,000. 76.20% of the stock is currently owned by institutional investors and hedge funds.

In other news, major shareholder Lilly Endowment Inc sold 200,000 shares of the company’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total value of $17,640,000.00. Following the transaction, the insider now directly owns 123,084,104 shares of the company’s stock, valued at $10,856,017,972.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Jeffrey N. Simmons sold 9,625 shares of the company’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $81.12, for a total transaction of $780,780.00. Following the completion of the transaction, the senior vice president now directly owns 152,120 shares in the company, valued at $12,339,974.40. The disclosure for this sale can be found here. Insiders sold 259,610 shares of company stock worth $22,727,406 over the last ninety days. 0.20% of the stock is currently owned by company insiders.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be paid a $0.5625 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.94%. Eli Lilly and’s dividend payout ratio is -1,040.00%.

COPYRIGHT VIOLATION WARNING: This story was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://theolympiareport.com/2018/02/14/equities-analysts-set-expectations-for-eli-lilly-and-cos-fy2018-earnings-lly.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.